Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles by Naito, M et al.
Identification of Lck-derived peptides applicable to anti-cancer
vaccine for patients with human leukocyte antigen-A3 supertype
alleles
M Naito
1,2, Y Komohara
1,3, Y Ishihara
1, M Noguchi
4, Y Yamashita
5, T Shirakusa
5, A Yamada
2,3, K Itoh
1,2 and
M Harada*,1,3
1Department of Immunology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan;
2Center of the 21st Century
COE Program for Medical Science, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan;
3Cancer Vaccine
Department Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi-machi, Kurume,
Fukuoka 830-0011, Japan;
4Department of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan;
5Department of Surgery, Fukuoka University School of Medicine, 45-1, 7-chome Nanakuma, Fukuoka, Fukuoka 814-0180, Japan
The identification of peptide vaccine candidates to date has been focused on human leukocyte antigen (HLA)-A2 and -A24 alleles. In
this study, we attempted to identify cytotoxic T lymphocyte (CTL)-directed Lck-derived peptides applicable to HLA-A11
þ, -A31
þ,
or -A33
þ cancer patients, because these HLA-A alleles share binding motifs, designated HLA-A3 supertype alleles, and because the
Lck is preferentially expressed in metastatic cancer. Twenty-one Lck-derived peptides were prepared based on the binding motif to
the HLA-A3 supertype alleles. They were first screened for their recognisability by immunoglobulin G (IgG) in the plasma of prostate
cancer patients, and the selected candidates were subsequently tested for their potential to induce peptide-specific CTLs from
peripheral blood mononuclear cells of HLA-A3 supertype
þ cancer patients. As a result, four Lck peptides were frequently
recognised by IgGs, and three of them – Lck90 99, Lck449 458, and Lck450 458 – efficiently induced peptide-specific and cancer-
reactive CTLs. Their cytotoxicity towards cancer cells was mainly ascribed to HLA class I-restricted and peptide-specific CD8
þ
T cells. These results indicate that these three Lck peptides are applicable to HLA-A3 supertype
þ cancer patients, especially those
with metastasis. This information could facilitate the development of peptide-based anti-cancer vaccine for patients with alleles other
than HLA-A2 and -A24.
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Many tumour antigens and their peptides that are recognised by
cytotoxic T lymphocytes (CTLs) have been identified from a
variety of cancer types (Renkvist et al, 2001), and subsequent
clinical applications, including a form of peptide-based immuno-
therapy, have been performed (Yamada and Itoh, 2006). Most of
these peptides are limited to human leukocyte antigen (HLA)-A2
or -A24 alleles, primarily because of the higher worldwide
frequency of these alleles (Imanishi et al, 1992). Several HLA
alleles are known to have structural similarities according to
peptide-binding motif analyses, and four supertypes have been
proposed: HLA-A2, -A3, -B7, and -B44 supertype alleles (Sette and
Sidney, 1999). Among them, the A3 supertype alleles include the
allelic products of at least five common HLA-A alleles, including
A3, A11, A31, A33, and A68. Thirty-eight percent of Caucasians,
53% of Chinese, 46% of Japanese, and 43% of North American
African Americans and Hispanics were positive for the HLA-A3
supertype alleles (Sette and Sidney, 1999). Therefore, the
identification of peptide vaccine candidates for HLA-A3 super-
type
þ cancer patients could facilitate the development of peptide-
based immunotherapy for many ethnic populations.
The Lck protein (p56
lck), the src family tyrosine kinase, is known
to be essential for both T-cell development and function (Veillette
et al, 1989). It is notable that the Lck protein is aberrantly
expressed in several malignancies, including colon carcinoma,
small cell lung carcinoma, and prostate carcinoma with a trend of
preferential expression in metastatic lesions (Robinson et al, 1996;
McCracken et al, 1997; Krystal et al, 1998; Lutz et al, 1998).
Although biological roles of the Lck protein in cancer cells have
not been fully confirmed, several lines of evidence suggest that this
protein contributes to the process of neoplastic transformation
(Marth et al, 1988; Robinson et al, 1996; McCracken et al, 1997;
Krystal et al, 1998; Lutz et al, 1998). In support of this idea, several
studies have reported that the Lck protein may contribute to the
anchorage-independent growth of TGF-b-initiated tumour cells
through the transcription of p56
lck with a type I promoter
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s(Amundadottir and Leder, 1998). In addition, we previously
reported that the Lck-derived peptides can be recognised by
cancer-reactive CTLs of cancer patients, and that Lck peptide-
specific CTLs can be induced from patients with distant
metastases, but not from those without distant metastases
(Harashima et al, 2001). In this study, we further attempted to
identify novel Lck-derived peptide candidates that would be
applicable to cancer patients with HLA-A3 supertype alleles to
expand the possibilities of a peptide-based vaccine for metastatic
cancer patients with alleles other than HLA-A2 and -A24.
MATERIALS AND METHODS
Patients
Peripheral blood mononuclear cells (PBMCs) were obtained from
prostate cancer patients who had provided written informed
consent. These patients included HLA-A11
þ, -A31
þ, and -A33
þ
patients, but PBMCs from HLA-A3
þ or -A68.1
þ patients were not
included because of their extremely low frequency (1.6 and 0.5%)
in the Japanese population (Aizawa, 1986). None of the subjects
were infected with HIV. Twenty millilitres of peripheral blood was
obtained, and PBMCs were prepared by Ficoll–Conray density
gradient centrifugation. All of the samples were cryopreserved
until they were used for the experiments. The expression of HLA-
A11, -A31, and -A33 molecules on PBMCs was determined by flow
cytometry using the following antibodies: anti-HLA-A11 mono-
clonal antibody (mAb) (cat. no. 0284HA; One Lambda Inc.,
Canoga, CA, USA), anti-HLA-A31 mAb (cat. no. 0273HA; One
Lambda), and anti-HLA-A33 mAb (cat. no. 0612HA; One Lambda).
Peptides
The Lck-derived peptides that are provided in Table 1 were
prepared on the basis of the binding motifs to the HLA-A11, -A31,
and -A33 molecules (Parker et al, 1994). All peptides were of
490% purity and were purchased from the Biologica Co. (Nagoya,
Japan). Epstein–Barr virus (EBV)-derived, tyrosinase-related
protein 2 (TRP-2)-derived, and HIV-derived peptides were used
as controls binding to HLA-A3 supertype alleles. All peptides were
dissolved with dimethyl sulphoxide at a dose of 10mgml
 1.
Measurement of IgGs reactive to Lck peptides
The levels of immunoglobulin Gs (IgGs) reactive to Lck peptides
were measured by the Luminext method, as reported previously
(Komatsu et al, 2004). In brief, 100ml of diluted plasma was
incubated with 5ml of colour-coded beads (Luminex Corp., Austin,
TX, USA) coated with each of the Lck peptides on 96-well filter
plates (MABVN1250; Millipore Corp., Bedford, MA, USA) for 2h at
room temperature on a plate shaker. The plates were then washed
with Tween-PBS and incubated with 100ml of biotin-conjugated
goat anti-human IgG (BA-3080: Vector Laboratories, Burlingame,
CA, USA) for 1h at room temperature on a plate shaker. After the
plates were washed, 100ml of streptavidin-PE was added to the
wells, and the samples were incubated for 30min at room
temperature on a plate shaker. The bound beads were washed
four times, and 100ml of Tween-PBS was added to each well. Fifty
microlitres of sample was examined using the Luminex system.
Induction of peptide-specific CTLs from PBMCs
The assay for the detection of peptide-specific CTLs was performed
according to a previously reported method with several modifica-
tions (Hida et al, 2002). In brief, PBMCs (1 10
5 cells per well)
were incubated with 10mlml
 1 of each peptide in quadruplicate in
a U-bottom-type 96-well microculture plate (Nunc, Roskilde,
Denmark) in 200ml of culture medium. The culture medium
consisted of 45% RPMI 1640, 45% AIM-V medium (Gibco BRL,
Gaithersburg, MD, USA), 10% FCS, 100Uml
 1 of interleukin-2
(IL-2), and 0.1mM MEM nonessential amino-acid solution (Gibco
BRL). Every 3 or 4 days, half the culture medium was removed and
replaced by new medium containing the corresponding peptide
(20mgml
 1) and 100Uml
 1 IL-2. On the fourteenth day of the
culture, the cultured cells were separated into four wells. Two wells
were used for the culture with the corresponding peptide-pulsed
C1R-A11, -A31, or -A33 cells, and the other two were used for the
culture with HIV peptide-pulsed C1R-A11, -A31, or -A33 cells.
After an 18-h incubation, the supernatant was collected, and the
level of interferon (IFN)-g was determined by enzyme-linked
immunosorbent assay. The successful induction of peptide-specific
CTLs was judged to be positive when a value of Po0.05 was
reached by a two-tailed Student’s t-test.
Cell lines
SQ-1 is an HLA-A11
þ lung carcinoma cell line. LC-1 is an HLA-
A31
þ and HLA-A33
þ lung carcinoma cell line. COLO 201 and
LNCaP are HLA-A3 supertype negative colon carcinoma and
prostate carcinoma cell lines, respectively. All tumour cell lines
were maintained in RPMI 1640 (Invitrogen) with 10% FCS. The
expression of the Lck protein on these cell lines was examined by
flow cytometry using anti-Lck mAb (mouse IgG2b) (sc-433; Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA), followed by FITC-
conjugated goat anti-mouse IgG no. 55493, Cappel ICN, Aurora,
Table 1 Summary of Lck-derived peptide candidates binding to the
HLA-A3 supertype alleles
Binding score
a
Peptides
Amino-acid
sequence
Bind
to
b A3 A11 A31 A33 A68
27–35 IVRLDGKGR 0.2 0.2 1 15 200
36–45 LLIRNGSEVR 6 0.12 4 9 10
37–45 LIRNGSEVR 0.4 0.08 2 15 5
90–99 ILEQSGEWWK 60 0.8 1 0.3 4.5
131–139 NLSRKDAER 4 0.08 2 9 7.5
146–154 NTHGSFLIR 1.8 0.4 4 3 50
198–207 TFPGLHELVR 0.012 0.08 1.2 3 0.75
290–299 NLMKQLQHQR 6 0.16 6 9 10
291–299 LMKQLQHQR 4 0.08 2 15 5
293–302 KQLQHQRLVR 1.08 1.08 24 0.9 10
294–302 QLQHQRLVR 8 0.16 4 9 5
354–363 FIEERNYIHR 1.2 0.16 4 15 7.5
379–387 KIADFGLAR 7.2 0.48 12 4.5 10
388–397 LIEDNEYTAR 0.4 0.08 2 15 5
429–438 LLTEIVTHGR 9 0.08 2 9 5
430–438 LTEIVTHGR 0.3 0.2 1 3 50
449–458 VIQNLERGYR 0.12 0.08 2 15 5
450–458 IQNLERGYR 0.036 0.12 2 3 5
452–461 NLERGYRMVR 24 0.16 4 9 5
471–480 QLMRLCWKER 3 0.08 3 9 10
472–480 LMRLCWKER 2 0.04 1 15
EBV IVTDFSVIK A11 10.0 4.0 0.6 0.5 240
Flu NVKNLYEKVK A11 3.0 1.0 0.1 0.5 180
TRP-2 LLGPGRPYR A31/
A33
6.0 0.1 2.0 9.0 15
HIV RLRDLLLIVTR A31 — — — — —
EBV¼Epstein–Barr virus; HLA¼human leukocyte antigen; TRP-2¼tyrosinase-
related protein 2.
aThe peptide-binding score was calculated based on the predicted
half time of dissociation from HLA class I molecules as obtained from a website
(Bioinformatics and Molecular Analysis Section, Computational Bioscience and
Engineering Laboratory, Division of Computer Research and Technology, NIH). The
binding score of the HIV peptide was not calculated because the peptide consisted of
11-mer amino acids.
bPreviously reported HLA class I alleles in which the peptides
have immunogenicity are shown.
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sOH, USA). Normal mouse IgG (sc-3879; Santa Cruz Biotechnology
Inc.) was used as a control for anti-Lck mAb.
Cytotoxicity assay
Peptide-stimulated PBMCs were tested for their cytotoxicity
against COLO 201 (HLA-A2
þ), SQ-1 (HLA-A11
þ), and LC-1
(HLA-A31
þ/A33
þ) by a standard 6-h
51Cr-release assay. Phyto-
haemagglutinin (PHA)-activated T cells were used as a negative
control. Two thousand
51Cr-labelled cells per well were cultured
with effector cells in 96-round well plates at the indicated effector/
target ratio. The specific
51Cr release was calculated according to
the following formula: (test c.p.m. spontaneous c.p.m.). Sponta-
neous release was determined by the supernatant of the sample
incubated with no effector cells, and the total release was then
determined by the supernatant of the sample incubated with 1%
Triton X (Wako Pure Chemical Industries, Osaka, Japan). In some
experiments, CD8
þ T cells were positively isolated using a CD8
Positive Isolation Kit (Dynal, Oslo, Norway). An measure of
10mgml
 1 of either anti-HLA class I (W6/32: mouse IgG2a) or
anti-HLA-DR (L243: mouse IgG2a) mAb was added into wells at
the initiation of the culture.
Cold inhibition assay
The specificity of peptide-stimulated CTLs against cancer cells was
confirmed by a cold inhibition assay. In brief,
51Cr-labelled target
cells (2 10
3 cells per well) were cultured with the effector cells
(2 10
4 cells per well) in 96-round well plates with 2 10
4 cold
target cells. C1R-A11, -A31, and -A33, which were pre-pulsed with
either the HIV peptide or a corresponding peptide, were used as
cold target cells.
Statistics
The statistical significance of the data was determined using a two-
tailed Student’s t-test. A P-value of less than 0.05 was considered
statistically significant.
RESULTS
Measurement of IgGs reactive to the Lck peptides in the
plasma of cancer patients
First, we prepared 21 peptides derived from the Lck protein based
on the binding motifs to the HLA-A3 supertype alleles (Table 1).
These include 9- and 10-mer peptides. Although the A3 supertype
alleles include HLA-A3 and -A68, we preferentially considered the
binding capacity to HLA-A11, -A31, and -A33 molecules because
the HLA-A3 and -A68 alleles are very rare in the Japanese
population (Aizawa, 1986). We first screened these peptide
candidates based on their recognisability by the IgGs of prostate
cancer patients, since we previously observed that IgGs reactive to
CTL-directed peptides are detectable in the plasma of patients with
different types of cancer (Nakatsura et al, 2002; Ohkouchi et al,
2002). In addition, the number of available PBMCs from prostate
cancer patients was limited, and 21 peptides was too large a
number of candidates to individually test their potential to
generate peptide-specific CTLs from the PBMCs of cancer patients.
The results were that IgGs reactive to the Lck90 99, Lck449 458,
Lck450 458, and Lck452 461 peptides were detected in the plasma of
9, 11, 7, and 5 out of the 20 prostate cancer patients, respectively
(Table 2). Immunoglobulin Gs reactive to the other 17 Lck peptides
were less frequently observed in the plasma of cancer patients
(data not shown).
Induction of peptide-specific CTLs from the PBMCs of
prostate cancer patients with HLA-A3 supertype alleles
We next determined whether or not these four Lck peptides, which
were more frequently recognised by IgGs in cancer patients than
were the other 17 peptides, could induce peptide-specific CTLs from
the PBMCs of HLA-A11
þ,- A 3 1
þ,o r- A 3 3
þ prostate cancer
patients. The PBMCs were stimulated in vitro with each of the Lck-
derived peptides or with a control peptide. The peptide-stimulated
PBMCs were then assessed for their IFN-g production in response to
corresponding peptide-pulsed C1R-A11, -A31, or -A33 cells. The
results of 17 patients (seven with HLA-A11, five with HLA-A31, and
five with HLA-A33) are shown in Table 3. Successful induction of
peptide-specific CTLs was judged to be positive when the P-value
was o0.05. As a result, the Lck90 99,L c k 449 458,L c k 450 458,a n d
Lck452 461 peptides induced corresponding peptide-specific CTLs
from the PBMCs of five, two, four, and three out of seven HLA-
A11
þ cancer patients. These peptides induced peptide-specific
CTLs from the PBMCs of three, three, four, and one out of five HLA-
A31
þ cancer patients, and of two, three, three, and one out of five
HLA-A33
þ cancer patients, respectively. In total, the Lck90 99,
Lck449 458,L c k 450 458, and Lck452 461 peptides induced correspond-
ing peptide-specific CTLs from the PBMCs of 10, 8, 11, and 5 out of
17 HLA-A3 supertype
þ cancer patients, respectively. These rates of
peptide-specific CTL induction were comparable with those of the
positive control EBV and TRP-2 peptides. These results suggest that
the Lck90 99,L c k 449 458, and Lck450 458 peptides have the potential
to efficiently generate peptide-specific CTLs in the PBMCs of
prostate cancer patients with HLA-A3 supertype alleles.
Induction of cancer-reactive CTLs from the PBMCs of
prostate cancer patients with HLA-A3 supertype alleles
Before the cytotoxicity assay, we selected target cancer cells that
express the HLA-A3 supertype alleles and the Lck protein. Flow
cytometric analysis revealed that HLA-A3 supertype negative colon
Table 2 IgG reactive to Lck peptides in the plasma of prostate cancer
patients
Patient Lck90–99 Lck449–458 Lck450–458 Lck452–461 No peptide
Immunofluorescence intensity
A 4 9 4 83 63 2 4 7
B 99 113 98 87 64
C 66 74 56 43 26
D3 3 132 63 40 46
E 92 123 96 82 47
F 15 16.5 12 10 7
G 1044 1361 1138 1096 447
H 5 4 6 94 85 5 6 2
I 100 86 75 134 49
J 4 4 5 23 73 4 3 6
K 64 65 46 40 24
L 3 6 4 33 32 9 2 0
M 319 274 228 213 80
N 3415 3489 3206 3217 1672
O 2 3 2 51 91 5 1 3
P 4 5 4 93 53 3 2 1
Q5 2 55 44 40 37
R 4 2 5 33 74 1 4 9
S 81 79 59 53 53
T 146 178 115 121 253
Positive/total 9/20 11/20 7/20 5/20
IgG¼immunoglobulin G. We measured the levels of peptide-specific IgG in the
plasma of 20 patients. The fluorescence intensity of the plasma (1:100 dilution) was
measured by the Luminex method. Positive results (4no peptide 1.5) are shown
in bold.
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scarcinoma COLO 201, HLA-A11
þ lung carcinoma SQ-1, and HLA-
A31
þ/A33
þ lung carcinoma LC-1 were positive for the Lck
protein (Figure 1). Although we had established several LNCaP
transfectants that express each of HLA-A11, -A31, and -A33
molecules (Minami et al, 2007), the LNCaP cell line was negative
for the Lck protein. Therefore, we used SQ-1 as an Lck-expressing
HLA-A11
þ target, and LC-1 as an Lck-expressing HLA-A31
þ/ 
A33
þ target. COLO 201 was used as an Lck-expressing HLA-A3
supertype negative target.
We then determined whether or not the CTLs induced by in
vitro stimulation with each of the Lck90 99, Lck449 458, and
Lck450 458 peptides could show cytotoxicity against cancer cells
(Figure 2). The PBMCs from HLA-A11
þ patients (patients 2, 6,
and 3), which were stimulated in vitro with each of the Lck90 99,
Lck449 458, and Lck450 458 peptides, exhibited higher levels of
cytotoxicity against HLA-A11
þ SQ-1 cells than against HLA-A11
 
COLO 201 cells and HLA-A11
þ PHA-stimulated T-cell blasts.
Similarly, these peptides possessed the ability to induce LC-1
(HLA-A31
þ/-A33
þ)-reactive CTLs from the PBMCs of HLA-
A31
þ and -A33
þ patients (patients 10, 11, and 13). Each of the
peptide-specific CTLs showed higher levels of cytotoxicity against
LC-1 cells than against COLO 201 cells or T-cell blasts. Taken
together, these results indicate that the PBMCs that were
stimulated in vitro with each of the Lck90 99, Lck449 458, and
Lck450 458 peptides can exhibit cytotoxicity against cancer cells in
an HLA-A11-, -A31-, or -A33-restricted manner.
Peptide-specific and CD8
þ T-cell-dependent cytotoxicity
against cancer cells
We further attempted to identify the cells responsible for the
cytotoxicity of Lck peptide-stimulated PBMCs. Purified CD8
þ T
cells were used in the following experiments. As shown in Figure 3,
the cytotoxicity of purified CD8
þ T cells from the peptide-
stimulated PBMCs against SQ-1 and LC-1 was significantly
decreased by the addition of anti-HLA class I mAb, but not by
the addition of anti-HLA class II (HLA-DR). In addition, the
cytotoxicity of these cells against SQ-1 and LC-1 was significantly
inhibited by the addition of corresponding peptide-pulsed
unlabelled C1R-A11, C1R-A31, and C1R-A33 cells, but not by the
addition of HIV peptide-pulsed unlabelled C1R-A11, C1R-A31, or
C1R-A33 cells (Figure 4). These results suggested that the
cytotoxicity of peptide-stimulated PBMCs against Lck-expressing
cancer cells was mainly dependent on HLA class I-restricted and
Lck peptide-specific CD8
þ T cells.
DISCUSSION
Although the Lck protein is known to be essential for both T-cell
development and function (Veillette et al, 1989), this protein is
aberrantly expressed in several malignancies, including colon
carcinoma, small cell lung carcinoma, and prostate carcinoma with
a trend of preferential expression in metastatic lesions (Robinson
et al, 1996; McCracken et al, 1997; Krystal et al, 1998; Lutz et al,
1998). We previously reported that HLA-A24-restricted tumour-
reactive CTLs from patients with distant metastases can recognise
Lck-derived peptides as a tumour antigen (Harashima et al, 2001).
We also identified Lck-derived peptides that were applicable to
metastatic cancer patients positive for HLA-A2 molecules (Imai
et al, 2001). Thereafter, we carried out peptide-based immuno-
therapy against various types of cancer in which Lck-derived
peptides were vaccinated into HLA-A24
þ or -A2
þ cancer patients
(Sato et al, 2003; Mine et al, 2004). The primary purpose of the
present study was to identify new Lck-derived peptides that would
be applicable to patients with HLA-A3 supertype alleles to expand
the possibilities for peptide-based anti-cancer vaccine for many
ethnic populations, as described in the Introduction.
We first screened 21 Lck peptide candidates based on their
ability to be recognised by the IgGs of cancer patients before
testing their ability to induce HLA class I-restricted CTLs, because
this approach was successful in our previous studies (Matsueda
et al, 2005; Minami et al, 2007). As a result, we selected four Lck
peptides that were frequently recognised by IgG. These candidates
were then tested for their ability to induce peptide-specific CTLs
from PBMCs of HLA-A3 supertype
þ cancer patients, and three of
them were found to effectively induce peptide-specific and cancer-
reactive CTLs. Although we did not include peptides that were
recognised by IgG less frequently in the CTL induction assay in
this study, we previously included them and compared to those
that were recognised by IgG more frequently. As a result, we
observed a correlation between their recognisability by IgG and the
induction rate of CTLs (Harada et al, 2004; Matsueda et al, 2005).
In our clinical trials, peptide vaccination frequently resulted in the
induction of IgGs reactive to the administered CTL-directed
peptides, and the induction of IgGs reactive to vaccinated peptides
was positively correlated with clinical responses and with the
survival of vaccinated patients (Sato et al, 2003; Mine et al, 2004).
Peptides that can be recognised by both CTLs and IgG might be
more useful in peptide-based immunotherapy than those that are
recognised only by CTLs.
Although we selected three Lck peptides from 21 candidates, the
most important point was to determine whether or not the selected
candidates could have the potential to induce cancer-reactive CTLs
in cancer patients. In this study, we demonstrated that three Lck
Table 3 Induction of peptide-specific CTLs from the PBMCs of HLA-
A11, -A31, and -A33 cancer patients
Peptide
Lck90–99 Lck449–458 Lck450–458 Lck452–461 EBV TRP-2 HIV
Patient IFN-c (pgml
 1)
HLA-A11
11 0 — 1 — 443 8—
2 40 15 — 54 3 36 —
3 150 57 37 —— 2 —
4 57 9 30 —2 28 —
5— 8 — — 1 2 —
6 60 116 44 34 1000 — 41
7 87 2 232 133 583 140 —
5/7 2/7 4/7 3/7 3/7 3/7 1/7
HLA-A31
81 5 6 — 2 6 1 1 4 —
92 2 1 7 72 15 43 17 —
10 34 98 23 30 32 40 —
11 127 34 341 11 40 89 —
12 299 96 118 31 12 — —
3/5 3/5 4/5 1/5 3/5 2/5 0/5
HLA-A33
13 151 55 28 13 48 19 —
14 14 — 24 — 207 2 —
15 61 60 105 15 39 157 —
16 9 100 16 26 —1 9—
17 3 6 — — 67 20 —
2/5 3/5 3/5 1/5 3/5 1/5 0/5
Positive/total 10/17 8/17 11/17 5/17 9/17 6/17 1/17
CTL¼cytotoxic T lymphocyte; HLA¼human leukocyte antigen; IFN-g¼interferon-
g; PBMC¼peripheral blood mononuclear cell. The PBMCs from HLA-A11, -A31,
and -A33 cancer patients were stimulated in vitro with the indicated Lck peptides. On
day 14, the cultured PBMCs were tested for their reactivity to C1R-A11, -A31, or
-A33 cells, which were pre-pulsed with a corresponding peptide or the HIV peptide.
The values represent the results of positive wells among four wells, and the
background IFN-g production in response to the HIV peptide was subtracted.
Significant values (Po0.05 by two-tailed Student’s t-test) are shown in bold.
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Figure 2 Cytotoxicity of peptide-stimulated PBMCs from HLA-A3 supertype
þ prostate cancer patients. Peptide-stimulated PBMCs from HLA-A3
supertype
þ prostate cancer patients were tested for their cytotoxicity towards three different targets by a 6-h
51Cr-release assay. Phytohaemagglutinin
(PHA)-stimulated T-cell blasts from HLA-A3 supertype
þ healthy donors were used as a control. *Statistically significant at Po0.05.
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Figure 1 The expression of the Lck protein in four tumour cell lines. These tumour cell lines were analysed by flow cytometry for their expression of the
Lck protein. These cells were stained first with anti-Lck mAb, followed by staining with FITC-conjugated anti-mouse IgG mAb. The grey background
represents staining first with normal mouse IgG, followed by staining with FITC-conjugated anti-mouse IgG mAb.
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speptides, Lck90 99, Lck449 458, and Lck450 458, could induce
cancer-reactive CTLs from the PBMCs of HLA-A3 supertype
þ
cancer patients. In addition, a cold inhibition assay revealed that
the cytotoxicity towards HLA-A3 supertype
þ cancer cells was
mainly dependent on Lck peptide-specific CD8
þ T cells. These
lines of evidence indicate that these Lck peptides would be useful
as a peptide-based anti-cancer vaccine for HLA-A3 supertype
þ
cancer patients.
The optimal COOH-terminal amino acid of A11-binding
peptides is lysine, and that of A31- or A33-binding peptides is
arginine (Rammensee et al, 1995; Sidney et al, 1996). Among the
three Lck peptides identified in this study to be candidates for
HLA-A3 supertype alleles, the Lck90 99 peptide carries lysine at the
COOH terminus, and both the Lck449 458 and Lck450 458 peptides
carry arginine at the COOH terminus. However, our results
revealed that the Lck90 99 peptide induced peptide-specific CTLs
from the PBMCs of HLA-A31
þ or -A33
þ cancer patients and, on
the other hand, both the Lck449 458 and Lck450 458 peptides
induced peptide-specific CTLs from the PBMCs of HLA-A11
þ
cancer patients. We reported a similar observation in our previous
study (Matsueda et al, 2005). These observations might suggest
that peptides carrying lysine or arginine at the COOH terminus fit
the binding motif for all HLA-A11, -A31, and -A33 molecules.
In conclusion, we identified three new peptide candidates that
were applicable to HLA-A3 supertype
þ cancer patients. In
combination with known Lck peptides for HLA-A2
þ or -A24
þ
cancer patients (Harashima et al, 2001; Imai et al, 2001), those
identified in the present study enable us to develop a peptide-
based anti-cancer vaccine for cancer patients with metastases in
diverse ethnic populations.
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Figure 3 Human leukocyte antigen class I-restricted cytotoxicity of peptide-stimulated PBMCs against cancer cells. Purified CD8
þ T cells from peptide-
stimulated PBMCs of HLA-A3 supertype
þ patients were tested for their cytotoxicity against HLA-A11
þ SQ-1 cells or HLA-A31
þ/A33
þ LC-1 cells in the
presence of the indicated mAbs by a 6-h
51Cr-release assay. *Statistically significant at Po0.05.
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Figure 4 Peptide-specific cytotoxicity against cancer cells. Purified CD8
þ T cells from peptide-stimulated PBMCs of HLA-A3 supertype
þ patients were
tested for their cytotoxicity against HLA-A11
þ SQ-1 cells or HLA-A31
þ/A33
þ LC-1 cells in the presence of unlabelled C1R-A11, -A31, or -A33 cells,
which were pre-loaded with either the corresponding peptide or the HIV peptide, by a 6-h
51Cr-release assay. *Statistically significant at Po0.05.
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